title: Clinical efficacy of peritoneovenous shunting for the treatment of severe ovarian hyperstimulation syndrome.
abstract: We investigated prospectively the clinical efficacy of a newly developed continuous autotransfusion system of ascites (CATSA) without protein supplement in patients with severe ovarian hyperstimulation syndrome (OHSS). Peritoneovenous shunting was used to recirculate ascites. The CATSA was performed for 5 h at a rate of 100-200 ml/h once a day. Eighteen patients were treated with the CATSA (CATSA group) and 36 were treated with an intravenous 37.5 g/day of albumin supplement (albumin group). Hospital stay was significantly shorter in the CATSA group than in the albumin group (10.0 +/- 5.7 versus 13.9 +/- 6.2 days, P < 0.01). Haematocrit value reached <40% significantly earlier in the CATSA group (on hospital days 3.9 +/- 3.2 versus 5.9 +/- 2.5, P < 0.01). Using a single procedure, haemoconcentration, urinary output and pulse pressure were markedly improved in the CATSA group compared with the albumin group. Discomfort due to massive ascites diminished promptly and did not recur in nine of 18 CATSA group patients, whereas it persisted in all 36 patients in the albumin group. The serum concentration of protein was maintained in the CATSA group, whereas it did not increase in the albumin group despite daily supplementation with 37. 5 g of albumin. Apparent adverse effects of each procedure were not observed in either group. The mean values of several parameters in the serum pertinent to the coagulation-fibrinolysis system did not change significantly in either group after the procedure. It was concluded that the CATSA procedure expanded circulating plasma volume without exogenous albumin and appeared to lead to a prompt recovery from severe conditions of OHSS.
authors.affiliation: Department of Obstetrics and Gynaecology, Jichi Medical School, Minamikawachi-machi, Tochigi, 329-04 Japan.
authors.forename: T
authors.initials: T
authors.lastname: Koike
authors.forename: S
authors.initials: S
authors.lastname: Araki
authors.forename: H
authors.initials: H
authors.lastname: Minakami
authors.forename: S
authors.initials: S
authors.lastname: Ogawa
authors.forename: M
authors.initials: M
authors.lastname: Sayama
authors.forename: H
authors.initials: H
authors.lastname: Shibahara
authors.forename: I
authors.initials: I
authors.lastname: Sato
mesh_terms: D000328:Adult; D000418:Albumins / Q000008:administration & dosage; D001201:Ascites / Q000601:surgery; D004231:Diuresis; D004232:Diuretics / Q000627:therapeutic use; D004624:Embryo Transfer; D005260:Female; D006400:Hematocrit; D006801:Humans; D007902:Length of Stay; D016471:Ovarian Hyperstimulation Syndrome / Q000601:surgery*; D010062:Ovulation Induction / Q000009:adverse effects; D010536:Peritoneovenous Shunt; D010953:Plasma Volume; D011247:Pregnancy; D011446:Prospective Studies; D011674:Pulse; D016896:Treatment Outcome
chemical_list: D000418:Albumins; D004232:Diuretics